Browse EyeWorld Weekly ophthalmology news on EyeWorld.org. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ ASCRS advocacy helps protect MIGS coverage ➤ FDA approves generic loteprednol etabonate ophthalmic suspension ➤ Orphan Drug Designation granted for corneal endothelial cell substitute ➤ Positive results in Phase 2 clinical trial for contact lens discomfort ➤ First patient visits ➤ Acquisition news ➤ Complimentary access to video journal ➤ ASCRS news and events
➤ Positive topline results in Phase 2a trial for treatment of MGD in patients with Demodex ➤ First patient visit in Phase 2b trial evaluating anti-TNFα for dry eye disease ➤ Smart contact lens makes progress ➤ Asset transition ➤ ASCRS news and events
➤ Primary, secondary endpoints met in Phase 2 wet AMD trial ➤ Modifications made to investigational glaucoma treatment device ➤ Positive Phase 1/2 data from clinical trial for treatment of Leber congenital amaurosis ➤ Results from first-in-human study of siRNA treatment for AMD ➤ Possibility of a minimally invasive approach for treating AMD ➤ ASCRS news and events
➤ First patient treated in Phase 2 study of investigational emulsion for glaucoma ➤ FDA issues complete response letter for dry eye drug NDA ➤ FDA meeting minutes issued for BLA submissions of ophthalmic formulation of bevacizumab ➤ Phase 1/2 trial to begin for first-in-class dry AMD therapy ➤ Company merger news ➤ ASCRS news and events
➤ World’s first whole-eye transplant ➤ Regenerative Medicine Advanced Therapy designation for investigational therapy for Leber congenital amaurosis ➤ 48-month trial data for retinal prosthesis for patients with severe atrophic AMD ➤ First patient dosed in Phase 1/2 trial for Stargardt disease gene therapy ➤ Partnership to develop molecule targeting DME ➤ ASCRS news and events
➤ 3-year efficacy and safety results of gene therapy for wet AMD reported ➤ Phase 2 trial results of gene therapy for diabetic retinopathy ➤ Phase 2 program for tracking glaucoma biomarkers begins ➤ Results from extension study of the first approved treatment for geographic atrophy ➤ Primary endpoint agreed upon for investigational oral diabetic retinopathy therapy ➤ ASCRS news and events
➤ FDA expands eye drop warning list ➤ Positive results in Phase 2a trial for new biodegradable sustained drug delivery implant ➤ Phase 2b study begins for investigational therapy for acute infectious conjunctivitis ➤ FDA approves additional treatment indication for bispecific antibody ➤ Enrollment complete for study evaluating femtosecond laser-created trabeculotomy ➤ Company to study personalized medicine for patients with wet AMD ➤ Enrollment complete for Phase 2b trial evaluating wet AMD therapy ➤ Pivotal trial for wet AMD therapy begins ➤ Survey evaluates female ophthalmologist experiences ➤ ASCRS news and events
➤ Editorial statement on the nomenclature for refractive lenticule extraction procedure ➤ First patient dosed in Phase 1/2 trial evaluating allogenic cell therapy for corneal edema ➤ IND granted to company investigating therapy for geographic atrophy ➤ Licensing agreement to develop neuroprotective drug ➤ Retinal imaging test detects increased risk for type of dementia ➤ ASCRS news and events
➤ FDA approves presbyopia drop ➤ FDA approves expanded capabilities on anterior segment diagnostic platform ➤ Phase 4 data presented for dry eye disease drug ➤ Extension study for investigational wet AMD treatment demonstrates safety, efficacy ➤ Reports suggest reproxalap NDA might not be approved ➤ Companies partner to develop gene therapy ➤ ASCRS news and events
➤ Positive Phase 3 results in trial investigating topical diabetic macular edema treatment ➤ Positive topline results in Phase 3 trials for retinal vein occlusion treatment ➤ IND filed for drug to treat neuropathic corneal pain ➤ Trial for ‘first-in-class anti-VEGF-complement dual targeting drug’ begins dosing patients ➤ Complimentary access to video journal ➤ ASCRS news and events